Can we prevent or treat renal dysfunction in chronic heart failure?

Heart Failure Reviews

Volumn 17, Issue 2, 2012, Pages 283-290

  Dobre, Daniela ^a,b   Rossignol, Patrick ^c   Metra, Marco ^d   Zannad, Faiez ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b European Drug Development Hub   (France)

^c INSERM   (France)

^d UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Chronic heart failure; Prevention; Renal dysfunction

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ERYTHROPOIETIN; FUROSEMIDE; IRON; LOOP DIURETIC AGENT; NATRIURETIC PEPTIDE TYPE C; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; THIAZIDE DIURETIC AGENT; WARFARIN;

AGE; ALGORITHM; ANEMIA; ARTICLE; CENTRAL VENOUS PRESSURE; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG MONITORING; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; IRON DEFICIENCY ANEMIA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; NEPHROTOXICITY; PREDICTION; PROTEINURIA; SYSTOLIC DYSFUNCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL MARKERS; CHRONIC DISEASE; COMORBIDITY; DIURETICS; HEART FAILURE; HUMANS; KIDNEY; KIDNEY DISEASES;

EID: 84862528257     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-011-9264-0     Document Type: Article

References (56)

1. Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38: 1933-1953
2. Renkin EM, Robinson RR (1974) Glomerular filtration. N Engl J Med 290: 785-792
3. Sawicki PT, Berger M (1994) Measuring progression of diabetic nephropathy. Eur J Clin Invest 24: 651-655
4. Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL (2006) Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114: 1572-1580
5. Dobre D, DeJongste MJ, Lucas C, Cleuren G, van Veldhuisen DJ, Ranchor AV, Haaijer-Ruskamp F (2007) Effectiveness of betablocker therapy in daily practice patients with advanced chronic heart failure; is there an effect-modification by age? Br J Clin Pharmacol 63: 356-364
6. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-1009
7. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955-962
8. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ (2000) Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210
9. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113: 671-678
10. Cauthen CA, Lipinski MJ, Abbate A, Appleton D, Nusca A, Varma A, Goudreau E, Cowley MJ, Vetrovec GW (2008) Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol 101: 1643-1647
11. Heywood JT, Elatre W, Pai RG, Fabbri S, Huiskes B (2005) Simple clinical criteria to determine the prognosis of heart failure. J Cardiovasc Pharmacol Ther 10: 173-180
12. Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1: 2-5
13. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N, EKnoyan G (2005) Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (kdigo). Kidney Int 67: 2089-2100
14. Jackson CE, Solomon SD, Gerstein HC, Zetterstrand S, Olofsson B, Michelson EL, Granger CB, Swedberg K, Pfeffer MA, Yusuf S, McMurray JJ (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374: 543-550
15. McCullough PA (2003) Why is chronic kidney disease the "Spoiler" for cardiovascular outcomes? J Am Coll Cardiol 41: 725-728
16. Pannarale G, Carbone R, Del Mastro G, Gallo C, Gattullo V, Natalicchio L, Navarra A, Tedesco A (2010) The aging kidney: structural changes. J Nephrol 23(Suppl 15): S37-S40
17. Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160: 685-693
18. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K (2008) Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the european society of cardiology. Developed in collaboration with the heart failure association of the esc (hfa) and endorsed by the european society of intensive care medicine (esicm). Eur J Heart Fail 10: 933-989
19. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589
20. Dobre D, Lambers Heerspink H, de Zeeuw D (2009) Reducing cardiovascular risk: protecting the kidney. Eur Heart J Suppl 11(Supplement F): F39-F46
21. Capes SE, Gerstein HC, Negassa A, Yusuf S (2000) Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care 23: 377-380
22. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J (1999) Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (solvd). Am Heart J 138: 849-855
23. Waeber B (2006) Managing hypertension in high-risk patients: lessons and promises from the strathe and advance trials. J Hypertens Suppl 24: S19-S27
24. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC (2006) Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296: 2217-2226
25. Ljungman S, Kjekshus J, Swedberg K (1992) Renal function in severe congestive heart failure during treatment with enalapril (the cooperative north scandinavian enalapril survival study [consensus] trial). Am J Cardiol 70: 479-487
26. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P (2008) Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 52: 818-827
27. van der Meer P, van Veldhuisen DJ (2009) Anaemia and renal dysfunction in chronic heart failure. Heart 95: 1808-1812
28. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032
29. Toblli JE, Lombrana A, Duarte P, Di Gennaro F (2007) Intravenous iron reduces nt-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 50: 1657-1665
30. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole- Wilson PA, Ponikowski P (2009) Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361: 2436-2448
31. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52: 1527-1539
32. Verma A, Anavekar NS, Meris A, Thune JJ, Arnold JM, Ghali JK, Velazquez EJ, McMurray JJ, Pfeffer MA, Solomon SD (2007) The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the valiant echo study. J Am Coll Cardiol 50: 1238-1245
33. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL (2009) Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53: 582-588
34. Damman K, Voors AA, Hillege HL, Navis G, Lechat P, van Veldhuisen DJ, Dargie HJ (2010) Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 12: 974-982
35. Jessup M, Costanzo MR (2009) The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol 53: 597-599
36. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL (2007) Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9: 872-878
37. Packer M (1988) Interaction of prostaglandins and angiotensin ii in the modulation of renal function in congestive heart failure. Circulation 77: I64-73
38. Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR (2009) Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the warfarin and antiplatelet therapy in chronic heart failure (watch) trial. Circulation 119: 1616-1624
39. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA (1998) Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular dysfunction (solvd) trial. J Am Coll Cardiol 31: 419-425
40. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M (2000) Are we inhibited? Renal insufficiency should not preclude the use of ace inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med 160: 2645-2650
41. Juhlin T, Bjorkman S, Gunnarsson B, Fyge A, Roth B, Hoglund P (2004) Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ace-inhibitors. Eur J Heart Fail 6: 909-916
42. Dobre D, Haaijer-Ruskamp FM, Voors AA, van Veldhuisen DJ (2007) Beta-adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. Drugs Aging 24: 1031-1044
43. Agostoni P, Marenzi G, Lauri G, Perego G, Schianni M, Sganzerla P, Guazzi MD (1994) Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 96: 191-199
44. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49: 675-683
45. Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592
46. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169: 1156-1162
47. Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, Wang X, Lash J, Lewis JA, Pogue V, Thornley- Brown D, Phillips RA (2009) Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169: 1587-1594
48. Weir MR, Maibach EW, Bakris GL, Black HR, Chawla P, Messerli FH, Neutel JM, Weber MA (2000) Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med 160: 481-490
49. Rimmer JM, Horn JF, Gennari FJ (1987) Hyperkalemia as a complication of drug therapy. Arch Intern Med 147: 867-869
50. Lisy O, Huntley BK, McCormick DJ, Kurlansky PA, Burnett JC Jr (2008) Design, synthesis, and actions of a novel chimeric natriuretic peptide: Cd-np. J Am Coll Cardiol 52: 60-68
51. Pan S, Chen HH, Dickey DM, Boerrigter G, Lee C, Kleppe LS, Hall JL, Lerman A, Redfield MM, Potter LR, Burnett JC Jr, Simari RD (2009) Biodesign of a renal-protective peptide based on alternative splicing of b-type natriuretic peptide. Proc Natl Acad Sci USA 106: 11282-11287
52. Navis G, de Zeeuw D, de Jong PE (1997) Ace-inhibitors: panacea for progressive renal disease. Lancet 349: 1852-1853
53. Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and gfr in the assessment of diabetic nephropathy. Nat Rev Nephrol 5: 397-406
54. Tang WH, Van Lente F, Shrestha K, Troughton RW, Francis GS, Tong W, Martin MG, Borowski AG, Jasper S, Starling RC, Klein AL (2008) Impact of myocardial function on cystatin c measurements in chronic systolic heart failure. J Card Fail 14: 394-399
55. Damman K, Van Veldhuisen DJ, Navis G, Vaidya VS, Smilde TD, Westenbrink BD, Bonventre JV, Voors AA, Hillege HL (2011) Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 96: 1297-1302
56. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ontarget study): a multicentre, randomised, doubleblind, controlled trial. Lancet 372: 547-553